Andreessen Horowitz Bio + Health
Venture fund
- Stages
- Seed, Series A, Series B
- Cheque size
- $1M to $50M
- Based in
- United States
- Focus
- Pharma & Drug Discovery, Clinical AI & Documentation, Metabolic Health
Andreessen Horowitz Bio + Health is the life sciences practice of the venture firm founded by Marc Andreessen and Ben Horowitz. Launched in 2015 under Vijay Pande, it invests where computer science meets life sciences, backing drug discovery, healthcare software and biotechnology companies.
Invests where biology, engineering and software converge, from drug discovery to care delivery.
Notable investments
- Devoted Health
- Insitro
- Freenome
The journey
How Andreessen Horowitz Bio + Health got here, step by step.
2009
Andreessen Horowitz founded
Marc Andreessen and Ben Horowitz founded the venture capital firm in Silicon Valley.
2015
First Bio Fund launches
The firm launched a two hundred million dollar Bio Fund led by new general partner Vijay Pande.
2015
Software meets biology thesis
The fund targeted startups applying computer science to drug discovery and healthcare delivery.
2020
Bio Fund III announced
A third bio fund arrived with partners including Vineeta Agarwala, Jorge Conde and Julie Yoo.
2021
Practice renamed Bio + Health
The practice broadened its name and mandate, reflecting a wider healthcare technology focus.
2022 to 2024
Team and fund size expand
The firm grew its bio and health team and raised further dedicated capital for life sciences.
Investors at similar stages
- 7wireVentures
Venture fund
- Bessemer Venture Partners
Venture fund
- CVS Health Ventures
Corporate venture
- Define Ventures
Venture fund
- Elad Gil
Angel investor
- EQT Life Sciences
Venture fund